{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:43:15Z","timestamp":1787236995154,"version":"build-2736575974"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vienna Business Agency","award":["1237261"],"award-info":[{"award-number":["1237261"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Bovine papillomaviruses types 1 and 2 (BPV1, BPV2) commonly induce skin tumours termed sarcoids in horses and other equids. Sarcoids seriously compromise the health and welfare of affected individuals due to their propensity to resist treatment and reoccur in a more severe form. We have developed influenza (Flu) A and B virus vectors that harbour a truncated NS1 gene (iNS) assuring interferon induction and co-express shuffled BPV1 E6 and E7 antigens for sarcoid immunotherapy. In a safety trial involving 12 healthy horses, intradermal administration of iNSA\/E6E7\n                    <jats:sup>equ<\/jats:sup>\n                    and iNSB\/E6E7\n                    <jats:sup>equ<\/jats:sup>\n                    was well tolerated, with the only transient side effect being mild fever in four horses. Repeated screening of secretions and faeces by RT-PCR and plaque assay revealed no virus shedding, thus also confirming biological safety. In a patient trial involving 29 horses bearing BPV1-induced single or multiple sarcoids, at least one lesion per horse was intratumourally injected and then boosted with iNSA\/E6E7\n                    <jats:sup>equ<\/jats:sup>\n                    and\/or iNSB\/E6E7\n                    <jats:sup>equ<\/jats:sup>\n                    . The treatment induced a systemic antitumour response as reflected by the synchronous regression of injected and non-injected lesions. Irrespective of vaccination schemes, complete tumour regression was achieved in 10\/29 horses. In 10\/29 horses, regression is still ongoing (May 2021). Intriguingly, scrapings collected from former tumour sites in two patients tested negative by BPV1 PCR. Nine severely affected individuals with a history of unsuccessful therapeutic attempts did not (6\/29) or only transiently (3\/29) respond to the treatment. INSA\/E6E7\n                    <jats:sup>equ<\/jats:sup>\n                    and iNSB\/E6E7\n                    <jats:sup>equ<\/jats:sup>\n                    proved safe and effective in significantly reducing the tumour burden even in severe cases.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0260155","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T13:32:05Z","timestamp":1637328725000},"page":"e0260155","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients"],"prefix":"10.1371","volume":"16","author":[{"given":"Christoph","family":"Jindra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Hainisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"R\u00fcmmele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wolschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Muster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3837-3422","authenticated-orcid":true,"given":"Sabine","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"issue":"Pt 5","key":"pone.0260155.ref001","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1099\/vir.0.18947-0","article-title":"Association of bovine papillomavirus with the equine sarcoid","volume":"84","author":"G Chambers","year":"2003","journal-title":"J Gen Virol"},{"issue":"7","key":"pone.0260155.ref002","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1128\/JCM.00371-13","article-title":"Bovine papillomavirus type 13 DNA in equine sarcoids","volume":"51","author":"M Lunardi","year":"2013","journal-title":"J Clin Microbiol"},{"key":"pone.0260155.ref003","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/j.ctep.2005.10.008","article-title":"A suggested clinical classification for the equine sarcoid","volume":"4","author":"DC Knottenbelt","year":"2005","journal-title":"Clinical Techniques in Equine Practice"},{"key":"pone.0260155.ref004","first-page":"719","volume-title":"Equine Dermatology","author":"DW Scott","year":"2003"},{"key":"pone.0260155.ref005","first-page":"389","volume-title":"Papillomavirus Research: From Natural History to Vaccines and Beyond","author":"L Nasir","year":"2006","edition":"1"},{"key":"pone.0260155.ref006","volume-title":"Robinson\u2019s Current Therapy in Equine Medicine.","author":"EK Hainisch","year":"2015","edition":"7"},{"key":"pone.0260155.ref007","first-page":"387","volume-title":"Pascoe\u2019s principles and practice of equine dermatology","author":"DC Knottenbelt","year":"2009"},{"issue":"2","key":"pone.0260155.ref008","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cveq.2019.03.006","article-title":"The Equine Sarcoid: Why Are There so Many Treatment Options?","volume":"35","author":"DC Knottenbelt","year":"2019","journal-title":"Vet Clin North Am Equine Pract."},{"key":"pone.0260155.ref009","first-page":"2197","volume-title":"Fields Virology","author":"PM Howley","year":"2001","edition":"4"},{"issue":"1\u20132","key":"pone.0260155.ref010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.vetmic.2013.08.003","article-title":"Papillomavirus associated diseases of the horse","volume":"167","author":"L Nasir","year":"2013","journal-title":"Vet Microbiol"},{"issue":"Pt 4","key":"pone.0260155.ref011","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1099\/vir.0.028191-0","article-title":"Different contribution of bovine papillomavirus type 1 oncoproteins to the transformation of equine fibroblasts","volume":"92","author":"Z Yuan","year":"2011","journal-title":"J Gen Virol"},{"issue":"2","key":"pone.0260155.ref012","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.virol.2007.11.037","article-title":"Establishment and characterization of equine fibroblast cell lines transformed in vivo and in vitro by BPV-1: model systems for equine sarcoids","volume":"373","author":"ZQ Yuan","year":"2008","journal-title":"Virology"},{"key":"pone.0260155.ref013","first-page":"373","volume-title":"Papillomavirus Research: From Natural History to Vaccines and Beyond","author":"MS Campo","year":"2006","edition":"1"},{"issue":"1","key":"pone.0260155.ref014","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-9378-8-26","article-title":"Bovine papillomavirus on the scene of crime: is E5 oncogene the only guilty party?","volume":"8","author":"G. Borzacchiello","year":"2013","journal-title":"Infect Agent Cancer"},{"key":"pone.0260155.ref015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1476-4598-10-140","article-title":"Papillomavirus E5: the smallest oncoprotein with many functions","volume":"10","author":"A Venuti","year":"2011","journal-title":"Mol Cancer"},{"issue":"Pt 12","key":"pone.0260155.ref016","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1099\/vir.0.014746-0","article-title":"Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain","volume":"90","author":"B Marchetti","year":"2009","journal-title":"J Gen Virol"},{"issue":"5","key":"pone.0260155.ref017","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2460\/ajvr.2001.62.741","article-title":"Bovine papillomavirus DNA in neoplastic and nonneoplastic tissues obtained from horses with and without sarcoids in the western United States","volume":"62","author":"EA Carr","year":"2001","journal-title":"Am J Vet Res"},{"issue":"1\u20132","key":"pone.0260155.ref018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-1702(03)00175-8","article-title":"Sequence variants of bovine papillomavirus E5 detected in equine sarcoids","volume":"96","author":"G Chambers","year":"2003","journal-title":"Virus Res"},{"issue":"3","key":"pone.0260155.ref019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/tvjl.2000.0524","article-title":"PCR detection of bovine papilloma virus DNA in superficial swabs and scrapings from equine sarcoids","volume":"161","author":"A Martens","year":"2001","journal-title":"Vet J"},{"issue":"Pt 12","key":"pone.0260155.ref020","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1099\/vir.0.066589-0","article-title":"Analysis of the long control region of bovine papillomavirus type 1 associated with sarcoids in equine hosts indicates multiple cross-species transmission events and phylogeographical structure","volume":"95","author":"H Trewby","year":"2014","journal-title":"J Gen Virol"},{"key":"pone.0260155.ref021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.virusres.2017.11.005","article-title":"Genomic comparison of bovine papillomavirus 1 isolates from bovine, equine and asinine lesional tissue samples","volume":"244","author":"C Koch","year":"2018","journal-title":"Virus Res"},{"issue":"1","key":"pone.0260155.ref022","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.vetmic.2012.08.030","article-title":"Genetic characterization of a novel bovine papillomavirus member of the Deltapapillomavirus genus","volume":"162","author":"M Lunardi","year":"2013","journal-title":"Vet Microbiol"},{"issue":"4","key":"pone.0260155.ref023","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ijc.30120","article-title":"Host genetic influence on papillomavirus-induced tumors in the horse","volume":"139","author":"EA Staiger","year":"2016","journal-title":"Int J Cancer"},{"issue":"2","key":"pone.0260155.ref024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/vco.12458","article-title":"Differentially expressed microRNAs, including a large microRNA cluster on chromosome 24, are associated with equine sarcoid and squamous cell carcinoma","volume":"17","author":"K Bogedale","year":"2019","journal-title":"Vet Comp Oncol"},{"issue":"Pt 10","key":"pone.0260155.ref025","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1099\/vir.0.033670-0","article-title":"Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation","volume":"92","author":"B Hartl","year":"2011","journal-title":"J Gen Virol"},{"issue":"2","key":"pone.0260155.ref026","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3181\/00379727-77-18750","article-title":"Cutaneous sarcoma-like lesions of the horse caused by the agent of bovine papilloma","volume":"77","author":"C Olson","year":"1951","journal-title":"Proc Soc Exp Biol Med"},{"issue":"5","key":"pone.0260155.ref027","first-page":"743","article-title":"Attempts to relate bovine papilloma virus to the cause of equine sarcoid: equidae inoculated intradermally with bovine papilloma virus","volume":"30","author":"WL Ragland","year":"1969","journal-title":"Am J Vet Res"},{"issue":"2","key":"pone.0260155.ref028","first-page":"183","article-title":"Transmission of equine sarcoid","volume":"30","author":"JL Voss","year":"1969","journal-title":"Am J Vet Res"},{"issue":"1","key":"pone.0260155.ref029","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/viro.1996.0220","article-title":"Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization","volume":"219","author":"R Kirnbauer","year":"1996","journal-title":"Virology"},{"issue":"6","key":"pone.0260155.ref030","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/21645515.2015.1136039","article-title":"Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases","volume":"12","author":"JG Skeate","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"pone.0260155.ref031","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0042-6822(95)80066-2","article-title":"T cell responses to BPV-4 E7 during infection and mapping of T cell epitopes","volume":"206","author":"GM McGarvie","year":"1995","journal-title":"Virology"},{"key":"pone.0260155.ref032","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pvr.2017.12.006","article-title":"Therapeutic vaccines for high-risk HPV-associated diseases","volume":"5","author":"A Chabeda","year":"2018","journal-title":"Papillomavirus Res."},{"key":"pone.0260155.ref033","doi-asserted-by":"crossref","first-page":"100176","DOI":"10.1016\/j.pvr.2019.100176","article-title":"Immunotherapy for HPV associated cancer","volume":"8","author":"IH Frazer","year":"2019","journal-title":"Papillomavirus Res"},{"issue":"9","key":"pone.0260155.ref034","doi-asserted-by":"crossref","DOI":"10.3390\/v9090254","article-title":"Immunopathogenesis of HPV-Associated Cancers and Prospects for Immunotherapy","volume":"9","author":"S. Smola","year":"2017","journal-title":"Viruses"},{"issue":"8","key":"pone.0260155.ref035","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1128\/JVI.72.8.6437-6441.1998","article-title":"Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells","volume":"72","author":"A Egorov","year":"1998","journal-title":"J Virol"},{"issue":"2","key":"pone.0260155.ref036","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/viro.1998.9508","article-title":"Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems","volume":"252","author":"A Garcia-Sastre","year":"1998","journal-title":"Virology"},{"key":"pone.0260155.ref037","first-page":"177","article-title":"Attenuated influenza virus vaccines with modified NS1 proteins","volume":"333","author":"JA Richt","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"issue":"23","key":"pone.0260155.ref038","doi-asserted-by":"crossref","first-page":"11621","DOI":"10.1128\/JVI.01645-06","article-title":"Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts","volume":"80","author":"B Ferko","year":"2006","journal-title":"J Virol"},{"issue":"16","key":"pone.0260155.ref039","doi-asserted-by":"crossref","first-page":"10672","DOI":"10.1128\/JVI.79.16.10672-10677.2005","article-title":"Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment","volume":"79","author":"C Kittel","year":"2005","journal-title":"J Virol"},{"issue":"6","key":"pone.0260155.ref040","doi-asserted-by":"crossref","first-page":"e5984","DOI":"10.1371\/journal.pone.0005984","article-title":"Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine","volume":"4","author":"J Romanova","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"pone.0260155.ref041","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1086\/649428","article-title":"A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1","volume":"201","author":"V Wacheck","year":"2010","journal-title":"J Infect Dis"},{"issue":"8","key":"pone.0260155.ref042","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1128\/CVI.00056-06","article-title":"Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge","volume":"13","author":"S Sereinig","year":"2006","journal-title":"Clin Vaccine Immunol."},{"issue":"9","key":"pone.0260155.ref043","doi-asserted-by":"crossref","first-page":"e0138722","DOI":"10.1371\/journal.pone.0138722","article-title":"Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach","volume":"10","author":"C Jindra","year":"2015","journal-title":"PLoS One"},{"key":"pone.0260155.ref044","first-page":"3 E26","article-title":"Generation of an Influenza A based therapeutic human papillomavirus (HPV) vaccine","volume":"22","author":"HB Jindra C","year":"2013","journal-title":"Experimental Dermatology"},{"issue":"11","key":"pone.0260155.ref045","doi-asserted-by":"crossref","first-page":"e0143269","DOI":"10.1371\/journal.pone.0143269","article-title":"Correction: Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach","volume":"10","author":"C Jindra","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0260155.ref046","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ijc.20078","article-title":"Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants","volume":"110","author":"T Muster","year":"2004","journal-title":"Int J Cancer"},{"issue":"21","key":"pone.0260155.ref047","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.1128\/JVI.00169-11","article-title":"Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture","volume":"85","author":"E Roethl","year":"2011","journal-title":"J Virol"},{"issue":"8","key":"pone.0260155.ref048","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1128\/jvi.70.8.5519-5524.1996","article-title":"African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses","volume":"70","author":"EA Govorkova","year":"1996","journal-title":"J Virol"},{"issue":"2","key":"pone.0260155.ref049","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.virol.2008.02.014","article-title":"A subset of equine sarcoids harbours BPV-1 DNA in a complex with L1 major capsid protein","volume":"375","author":"S Brandt","year":"2008","journal-title":"Virology"},{"issue":"2","key":"pone.0260155.ref050","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1099\/jgv.0.000673","article-title":"Potential of a BPV1 L1 VLP vaccine to prevent BPV1- or BPV2-induced pseudo-sarcoid formation and safety and immunogenicity of EcPV2 L1 VLPs in horse","volume":"98","author":"EK Hainisch","year":"2017","journal-title":"J Gen Virol"},{"issue":"3","key":"pone.0260155.ref051","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"13","author":"SM Nguyen","year":"2015","journal-title":"Vet Comp Oncol."},{"key":"pone.0260155.ref052","first-page":"68","article-title":"How to Treat Equine Sarcoids by Autologous Implantation","volume":"54","author":"BMK Espy","year":"2008","journal-title":"AAEP Proceedings"},{"issue":"7","key":"pone.0260155.ref053","first-page":"709","article-title":"Autologous vaccination for the treatment of equine sarcoids: 18 cases (2009\u20132014)","volume":"56","author":"CC Rothacker","year":"2015","journal-title":"Can Vet J"},{"issue":"21","key":"pone.0260155.ref054","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.vaccine.2009.02.087","article-title":"Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate","volume":"27","author":"N Wressnigg","year":"2009","journal-title":"Vaccine"},{"key":"pone.0260155.ref055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tvjl.2016.07.012","article-title":"Immune response to bovine papillomavirus type 1 in equine sarcoid","volume":"216","author":"S. Brandt","year":"2016","journal-title":"Vet J"},{"key":"pone.0260155.ref056","first-page":"1","volume-title":"Papillomavirus Research: From Natural History to Vaccines and Beyond","author":"MS Campo","year":"2006","edition":"1"},{"issue":"Suppl 1","key":"pone.0260155.ref057","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.jcv.2004.12.006","article-title":"The papillomavirus life cycle","volume":"32","author":"J. Doorbar","year":"2005","journal-title":"J Clin Virol"},{"issue":"1\u20132","key":"pone.0260155.ref058","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-0378(01)00113-9","article-title":"Immunobiology of papillomavirus infections","volume":"52","author":"MA Stanley","year":"2001","journal-title":"J Reprod Immunol"},{"issue":"22","key":"pone.0260155.ref059","first-page":"8188","article-title":"A genetically engineered influenza A virus with ras-dependent oncolytic properties","volume":"61","author":"M Bergmann","year":"2001","journal-title":"Cancer Res"},{"issue":"6946","key":"pone.0260155.ref060","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature01783","article-title":"Viral infection switches non-plasmacytoid dendritic cells into high interferon producers","volume":"424","author":"SS Diebold","year":"2003","journal-title":"Nature"},{"issue":"4","key":"pone.0260155.ref061","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/JVI.01317-09","article-title":"Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses","volume":"84","author":"SN Mueller","year":"2010","journal-title":"J Virol"},{"issue":"2","key":"pone.0260155.ref062","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00430-009-0139-0","article-title":"Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells","volume":"199","author":"H Ogbomo","year":"2010","journal-title":"Med Microbiol Immunol"},{"issue":"28","key":"pone.0260155.ref063","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1016\/j.vaccine.2019.05.013","article-title":"Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1","volume":"37","author":"C Nicolodi","year":"2019","journal-title":"Vaccine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T13:33:13Z","timestamp":1637328793000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260155"}},"subtitle":[],"editor":[{"given":"Paulo Lee","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":63,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0260155","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]}}}